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Abstract
Background: This experimental study was performed to determine the impact of opium use on serum lipid profile and glucose metabo-
lism in rats with streptozotocin-induced diabetes.
Material and methods: To determine the effect of opium, 20 male rats were divided into control (n = 10) and opium-treated (n = 10)
groups. After diabetes induction, the animals were investigated for daily glucose measurements for 35 days. Serum lipid profile and
haemoglobin A1c (HbA1c) were assayed at the baseline (before induction of diabetes) and at 35-day follow-up.
Results: The glycaemia levels in the rats treated with opium were similar to the levels measured in the control rats (544.8 ± 62.2 mg/dl v.
524.6 ± 50.0 mg/dl, P = 0.434). In addition, there was no difference between the opium-treated rats and control rats in HbA1c (6.5 ± 0.5% v.
6.6 ±  0.2%, P = 0.714). Compared to the control rats, the serum total cholesterol, high density lipoprotein (HDL), triglyceride and lipopro-
tein (a) in the test animals were similar.
Conclusion: Opium use has no significant effect on glucose metabolism and serum lipid profile in rats with induced diabetes.
(Pol J Endocrinol 2009; 60 (4): 258–262)
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Streszczenie
Wstęp: To eksperymentalne badanie przeprowadzono w celu określenia wpływu stosowania opium na profil lipidowy i metabolizm
glukozy u szczurów z cukrzycą wywołaną podaniem streptozotocyny.
Materiał i metody: Aby ocenić wpływ opium 20 samców podzielono na dwie grupy: kontrolną (n = 10) i otrzymującą opium (n = 10). Po
wywołaniu cukrzycy przez 35 dni codziennie mierzono stężenie glukozy we krwi zwierząt. Profil lipidowy i odsetek hemoglobiny A1c
(HbA1c) określono na poczatku badania (przed wywołaniem cukrzycy)  i w 35. dniu obserwacji.
Wyniki: Poziom glikemii u szczurów, którym podawano opium i w grupie kontrolnej był podobny (544,8 ± 62,2 mg/dl v. 524,6 ± 50,0 mg/dl,
P = 0,434). Ponadto, nie stwierdzono różnic między grupą leczoną i kontrolną w zakresie wartości HbA1c (6,5 ± 0,5% v. 6,6 ± 0,2%, P = 0,714).
Również stężenia cholesterolu całkowitego, cholesterolu frakcji HDL, triglicerydów i lipoproteiny (a) były podobne w obu grupach.
Wnioski: Stosowanie opium nie ma istotnego wpływu na metabolizm glukozy i profil lipidowy u szczurów z eksperymentalnie wywo-
łaną cukrzycą. (Endokrynol Pol 2009; 60 (4): 258–262)
Słowa kluczowe: opium, szczury z cukrzycą streptozotocynową, glukoza, lipidy
Introduction
More than 180 million people around the world have
tried illegal drugs at least once. Of these people,
13.5 million are opium dependents. According to the U.N.
World Drug Report for 2005, Iran has the highest pro-
portion of opiate addicts in the world. It is estimated
that about 4 million Iranians regularly or occasionally
use opium, typically in the form of inhalation or oral
intake [1–3]. Opium is commonly consumed throughout
the nation, and after tobacco is the most widely abused
substance in Iran. For centuries in Iran it was regarded
as a privilege of the elderly, a largely medicinal comfort
for pains, diarrhoea, insomnia, premature ejaculation,
and worries accumulated over a lifetime of work and
enjoyment [4–6]. However, it has been shown that
opium abuse is a common problem among diabetic pa-
tients and is associated with severe depression and
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cigarette smoking [7]. Some of these problems arise from
the conception of traditional medicine.
In two recent studies, the prevalence of opium con-
sumption in patients with coronary artery disease was
significantly higher in than the statistics in official re-
ports from the general population of Iran [8, 9]. Opioid
peptides, particularly enkephalins, may play an impor-
tant role in a number of physiological and pathological
conditions in the heart such as ischaemic preconditio-
ning [IPC] via K+-ATP channel in cardiac mitochon-
dria [10, 11]. It has been reported that diabetes is asso-
ciated with a change of morphine antinociception and
the development of tolerance or dependency to opio-
ids. Hyperglycaemia in diabetes may alter hypothala-
mic-pituitary function, including the activity of the en-
dogenous opiate system. These changes appear to mo-
dulate opioid antinociception and basal nociceptive
processes [12, 13]. There are also several reports indica-
ting that experimental diabetes mellitus attenuates the
antinociceptive effect of morphine in animals [14, 15].
Recent clinical studies have reported controversial fin-
dings in terms of the effect of opium on serum electroly-
tes, lipid markers, and glucose metabolism [16, 17]. Ho-
wever, opium, opium alkaloids, and other alkaloids like
quinine or Belladonna alkaloid agents were most widely
used in Europe in the pre-insulin era as they were consi-
dered to have hypoglycaemic activity [18, 19]. To the best
of our knowledge, there is little information on the effect
of opium use in endocrine comorbidities in experimen-
tal models. Our study represents the direct quantifica-
tion of the serum lipid profile and glucose metabolism in
opium-treated rats after the induction of diabetes.
Material and methods
Animals, drug
Twenty male Sprague-Dawley rats weighing average
of 250 ± 30 g were used in this study. The rats were
transported to the Basic Research laboratory one week
prior to the test day to allow acclimatisation and reco-
very from transport and handling. All animals were
housed in an animal care facility under conditions of
controlled light, 12 h light/dark, at 24 ± 1°C temperatu-
re and 55 ± 5% humidity, with standard chow diet and
water available ad libitum. The investigation was ap-
proved by the institutional Review Board overseeing
the participation of animal subjects in research at Teh-
ran University of Medical Sciences, and the respective
local government committee, which is advised by an
independent ethics committee in our Cardiovascular
Research Centre. This study conforms to the ‘Guide for
the Care and Use of Laboratory Animals’ published by
the US National Institute of Health (NIH publication
No. 85–23, revised 1996). The experiments were carried
out on two main diabetic groups: opium-treated (test
group n = 10) and control (n = 10). The test rats rece-
ived normal opium 20 mg dissolved in their 30 ml daily
water intake, starting on the fifth day after induction of
diabetes, for 30 days.
Induction of diabetes
Experimental diabetes was induced in all animals by
a single dose injection of streptozotocin (STZ) (Zano-
sar, Pharmacia & Upjohn Company, Michigan, USA),
50 mg/kg intraperitoneally. Five days were allowed for
destruction of pancreatic beta cells and development
of Type 1 diabetes mellitus. Daily, the blood samples
were collected and their glucose levels measured. The
animals with blood glucose levels less than 300 mg/dL
were not used in the study.
Blood sampling and laboratory assessments
Blood samples for glucose measurements were obtained
by tail tip removal technique (Institutional Animal Care
and Use Committee Guideline 9, 1999). In a sterile situ-
ation, a transverse section was made through the long
axis of the tail 2 mm from the tip. After blood sampling,
direct pressure was applied to the incision for 1–3 mi-
nutes to facilitate haemostasis. Repeated blood sampling
was obtained by removing the clot. The blood glucose
was measured daily by Accu-Check glucometer (Roche
Diagnostics GmbH, D-68298 Mannheim, Germany)
qualified in the Quality Control Department.
On the first and last days of the experiment, each
rat received general anaesthesia by ketamine (50 mg/kg,
i.p.) and lidocaine (5 mg/kg, i.p.) to obtain intracardiac
blood collection (Intracardiac Blood Collection in Mice
and Rats, Canadian Council Animal Care Guide regar-
ding the Care and Use of Experimental Animals, 2008).
In the ventral midline approach, a 2 cc syringe needle
with 25 gauge needle was introduced just to the left of
the base of the animal’s sternum towards the heart at
an angle of approximately 20–30°. After full collection
of the blood sample, we safely removed and discarded
the needle. The blood samples were used to measure
haemoglobin A1C (HbA1c), lipoprotein a (LPa), total
cholesterol, triglyceride, and high density lipoprotein
(HDL). HbA1c was measured by using a bench top Ny-
coCard® HbA1c Reader II (Oslo, Norway) certified by
the National Glycohaemoglobin Standardization Pro-
gram, USA, September 2008. Serum levels of total cho-
lesterol, triglyceride, HDL, and LPa were assayed using
commercially available enzymatic kits (Pars Azmoon,
Tehran, Iran), cholesterol and triglyceride using enzy-
matic colorimetric tests, HDL by precipitation of the
apolipoprotein B100 containing lipoproteins with pho-
sphotungstic acid, and LPa by immunoturbidimetric
assay.
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Table I. Lipid profiles and glucose marker of the streptozotocin-diabetic rats (n = 20)
Tabela I. Profil lipidowy i wskaźniki stężenia glukozy u szczurów, którym podano streptozoocynę (n = 20)
Opium-treated (n = 10) Control (n = 10) p value
Baseline
Glucose [mg/dL-1] 112.2 ± 15.8 ** 108.2 ± 15.9 * 0.579
HbA1c (%) 2.6 ± 0.2 ** 2.6 ± 0.3 0.451
Triglyceride [mg/dL-1]  99.1 ± 8.5 ** 96.9 ± 11.3 * 0.629
Total Cholesterol [mg/dL-1] 107.7 ± 10.7 ** 102.9 ± 11.9 0.356
HDL [mg/dL-1] 42.1 ± 4.9 40.5 ± 3.9 0.430
LPa [mg/dL-1] 6.8 ± 1.9 6.9 ± 1.4 0.895
35-day follow-up
Glucose [mg/dL-1] 544.8 ± 62.2 ** 524.6 ± 50.0 * 0.434
HbA1c (%) 6.5 ± 0.5 ** 6.6 ± 0.2 * 0.714
Triglyceride [mg/dL-1] 105.1 ± 4.8 ** 102.9 ± 8.0 * 0.467
Total Cholesterol [mg/dL-1] 113.5 ± 13.4 ** 106.5 ± 15.0 0.287
HDL [mg/dL-1] 40.5 ± 3.7 39.8 ± 2.8 0.632
LPa [mg/dL-1] 6.5 ± 1.4 7.3 ± 0.9 0.158
Abbreviations: HbA1c, haemoglobin A1c; [LPa], lipoprotein a; HDL, high density lipoprotein; *p values were < 0.05 and based on a paired t test to
compare data of baseline and 35-day follow-up within control rats; **p values were < 0.05 and based on a paired t test to compare data of baseline
and 35-day follow-up within opium-treated rats
At the end of the experiments, all the animals were
sacrificed using an i.p. injection of 100 mg/kg sodium
thiopental.
Statistical analysis
Data from the baseline and the last day were expressed
as mean ± SD and were analysed by using Student
t test and paired t test to compare before and after inte-
rvention levels of favorable parameters in each group.
Modelling the mean glucose over time was the main
feature of analysis that we followed to deal with the
longitudinal data during the 35-day experiment. We
performed general linear model repeated measures
analysis to compare the concentrations of glucose across
the two groups (i.e., groups-by-time interaction). If the
sphericity assumption was not satisfied (Mauchly’s test
of sphericity, p £ 0.05), the Greenhouse-Geisser cor-
rection was reported. All statistical analyses were per-
formed using Statistical Package for Social Science ver-
sion 15 (SPSS Inc., Chicago, IL, USA). Probability valu-
es of P < 0.05 were considered statistically significant.
Results
The data of serum lipid profile, glucose, and HbA1c at
the baseline and on the last day of 35-day follow-up are
shown in Table I. Total cholesterol, LPa, triglyceride,
and HDL showed no significant differences between
the control and opium-treated animals. In both control
and opium-treated rats, levels of triglyceride and were
significantly increased from the baseline to the last day;
96.9 ± 11.3 mg/dL v. 102.9 ± 8.0 mg/dL, p = 0.015 and
99.1 ± 8.5 mg/dL v. 105.1 ± 4.8 mg/dL, p = 0.028, re-
spectively. In the opium-treated rats, the increase of total
cholesterol was also evident in a comparison between
the baseline and follow-up data [107.7 ± 10.7 mg/dL v.
113.5 ± 13.4 mg/dL, p = 0.016].
In both groups, serum glucose was significantly in-
creased on day 3 of diabetes induction and reached abo-
ve 500 mg/dL within 5 days. Serum glucose between
the groups was not significantly different at any time
during 35-day follow-up. There was no significant in-
teraction of group × time in repeated measure analysis
[Fig. 1, F = 1.310, p = 0.240].
Discussion
Our main objectives were to evaluate the effects of ava-
ilable opium substance on glucose and lipid metabo-
lism in STZ-diabetic rats. Here, the tested opium was
a mixture of about 50 different samples. Crude opium
contains the juice of the seed capsule of the opium pop-
py Papaver sotnniferum. The available substance was the
dry, sticky or crumbly dark mass that is known as raw
opium [20]. The major constituents of crude opium are
morphine (approximately 10% by weight), noscapine
(approximately 6%), papaverine (approximately 1%),
codeine (approximately 0.5%) and thebaine (approxi-
mately 0.2%). However, the available substance may
contain other constituents. The results of this experi-
mental study demonstrated that opium, as an accessi-
ble substance which is generally used by Iranian ad-
dicts, has no effect on glucose metabolism or lipid pro-
files in rats with STZ-induced diabetes. Although the
lipid indices were significantly increased after diabetes
induction, no rats developed dyslipidaemia. This result
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is consistent with some earlier studies. Azod et al. [16]
showed that while opium use may decrease blood glu-
cose temporarily in patients with type 2 diabetes, it had
no clear long-term effects on blood glucose and HbA1c.
Karam et al. reported that addicted males with nonin-
sulin-dependent diabetes mellitus had higher levels of
HbA1c, but lower levels of serum total protein and HDL.
Cholesterol tends to be lower in diabetic addicted ma-
les, while HbA1c in addicted females was higher com-
pared to non-addicted diabetics. Therefore, it was sug-
gested that smoking opium increases serum glucose and
decreases HDL, and thus adds to metabolic disorders
in diabetic patients [17].
Some others have shown impaired glucose metabo-
lism in opiate users. Ceriello et al. [21] found that pla-
sma glucose and insulin responses in heroin and me-
thadone addicts were altered according to oral and in-
travenous glucose load; the phenomena were linked to
a reduced insulin response. In another study by Passa-
riello et al. [22] the heroin users had a significant rise in
plasma glucose concentrations following oral sugar,
which persisted until the end of the study, and a signi-
ficant decrease in insulin response. Moreover, the inhi-
bitory effect of glucose on glucagon concentration was
less evident in addicts compared with controls. Opiate
addiction may produce a beta-cell dysfunction and,
contemporaneously, a state of hyperinsulinaemia. A
change in the rate of hepatic extraction of insulin and
lower glucose disappearance rate has been reported in
heroin addicts [23–25]. The finding of beta-endorphin
and enkephalin in the human pancreas may suggest
the direct effect of exogenous opiates on beta cell func-
tion [24, 26, 27].
Insulin and glucagon release from monolayer pan-
creatic islet cell cultures are inhibited in a dose-respon-
se fashion by various enkephalins. Morphine, however,
stimulates insulin and glucagon release [28]. The effects
of opioids on glucose homeostasis may not depend only
on insulin. An activation of opioid receptors by either
exogenous beta-endorphin or chemical agents, such as
loperamide and tramadol, has been shown [29–31].
Tzeng et al. [30] found that loperamide, a selective ago-
nist of opioid m-receptor has the ability to increase glu-
cose utilization and/or reduce hepatic gluconeogenesis
in the liver of STZ-diabetic rats. It was hypothesized
that loperamide enhances glucose uptake via an effect
on the gene expression of glucose transporter 4 [GLUT-
4] in skeletal muscle [32]. Moreover, this agent rever-
sed the elevated mRNA and protein levels of phospho-
enolpyruvate carboxykinase [PEPCK] in the liver of
STZ-diabetic rats to near normal levels [30]. Therefore,
it may modulate glucose homeostasis in diabetic rats
without the presence of insulin. Insulin deficiency is
clearly associated with changes in hepatic metabolism,
including increased expression of PEPCK, which is
a key enzyme of hepatic carbohydrate metabolism [33].
Decreased expression of skeletal muscle GLUT 4 was
proposed previously to mediate the reduction of insu-
lin-mediated glucose uptake into skeletal muscle in dia-
betes [34]. There is evidence that there is bidirectional
cross-talk between the endogenous opioid system and
glucose metabolism. Hyperglycaemia is associated with
analgesia in rats and this hyperglycaemia-induced anal-
gesia could be blocked by antagonists of opioids recep-
tors [35]. The interaction between glucose and the opioid
system is also supported by the report indicating dia-
betic and non-diabetic rats responded differently to the
suppressive effect of naloxone on feeding [36].
Morley et al. [37] indicated that morphine addiction
in rats was accompanied by an increase in brain levels
of somatostatin, cholecystokinin, neurotensin, and sub-
stance P, and that naloxone-induced withdrawal decre-
ased brain concentrations of TRH, somatostatin, neu-
rotensin, and substance P. The expression of beta-en-
dorphin sensitive receptor on skeletal muscle is vastly
increased in type 1 and type 2 diabetic animals [38]. In
other aspects, high plasma levels of [Met5]-enkephalin
[39] have been reported in patients with diabetes, whe-
reas Vermes et al. [40] observed normal levels of b-en-
dorphin in diabetic patients; however, Cheung and
Figure 1. Estimated marginal means of serum glucose level [mg/
/dL] in rats with induced diabetes comparing the opium-treated
and control groups; Greenhouse-Geisser test, p = 0.240
Rycina 1. Oszacowane średnie brzegowe stężeń glukozy
w surowicy [mg/dl] szczurów z wywołaną doświadczalnie cukrzycą
w porównaniu ze zwierzętami leczonymi opium i z grupą
kontrolną; test Greenhouse’a-Geissera, p = 0,240
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Tang [41] observed a decrease in b-endorphin levels in
the rat neuro-intermediate pituitary compared to ele-
vated levels in the anterior pituitary. Nevertheless, the
controversies in current evidence assessed the interac-
tion of opioids and endocrine system originates from
different methodological strategies. Thus, further inve-
stigation is needed to assess the specific roles of the dif-
ferent opioid peptides and/or the mixture of exogeno-
us opiates in the level of activation of opioid receptors
related to the glucose-modifying pathways.
Conclusions
In conclusion, it is suggested that chronic opium use
appears to have no considerable effect on serum gluco-
se and lipid metabolism in streptozotocin-diabetic rats.
Therefore, the utility of opium may have no effect on
reduction of cardiovascular risk factor in diabetics.
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